PKO Investment Management Joint Stock Co Reduces Stock Holdings in DexCom, Inc. $DXCM

PKO Investment Management Joint Stock Co reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 63.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,900 shares of the medical device company’s stock after selling 34,100 shares during the period. PKO Investment Management Joint Stock Co’s holdings in DexCom were worth $1,250,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of DXCM. Brookstone Capital Management grew its stake in shares of DexCom by 23.8% in the 1st quarter. Brookstone Capital Management now owns 5,152 shares of the medical device company’s stock valued at $324,000 after buying an additional 990 shares during the period. SG Americas Securities LLC raised its position in shares of DexCom by 271.4% during the 1st quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock valued at $129,699,000 after buying an additional 1,509,219 shares during the period. Rockefeller Capital Management L.P. lifted its holdings in DexCom by 6.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 15,679 shares of the medical device company’s stock valued at $1,041,000 after acquiring an additional 938 shares during the last quarter. World Investment Advisors lifted its holdings in DexCom by 34.6% in the fourth quarter. World Investment Advisors now owns 65,089 shares of the medical device company’s stock valued at $4,320,000 after acquiring an additional 16,749 shares during the last quarter. Finally, Corient Private Wealth LLC grew its position in DexCom by 241.1% in the fourth quarter. Corient Private Wealth LLC now owns 123,754 shares of the medical device company’s stock worth $8,221,000 after acquiring an additional 87,468 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the sale, the insider directly owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. This represents a 6.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares in the company, valued at $7,075,708.50. The trade was a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,694 shares of company stock valued at $3,343,977 over the last quarter. Insiders own 0.28% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $69.07 on Tuesday. The business’s 50-day moving average is $67.13 and its two-hundred day moving average is $67.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm has a market capitalization of $26.65 billion, a P/E ratio of 29.52, a P/E/G ratio of 1.13 and a beta of 1.45. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the company posted $0.32 earnings per share. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. Analysts anticipate that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Bank of America reduced their target price on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Canaccord Genuity Group set a $82.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Monday, May 18th. Sanford C. Bernstein set a $77.00 target price on shares of DexCom in a research report on Friday, May 1st. Raymond James Financial reaffirmed a “strong-buy” rating and set a $91.00 target price on shares of DexCom in a research note on Monday, June 8th. Finally, Mizuho set a $85.00 price target on shares of DexCom and gave the company an “outperform” rating in a research report on Tuesday, June 9th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $84.83.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.